Luminescens® offers a standalone or adjunctive protocol for treating recalcitrant dyschromia conditions, strategically targeting the multifaceted melanogenesis pathway to deliver sustained, clinically validated results.
Hyperpigmentation disorders, notably melasma, post- inflammatory hyperpigmentation (PIH) and solar lentigines, are characterised by dysregulated melanocyte activity, resulting in excessive melanin production and deposition. These conditions commonly resist conventional interventions that only superficially address pigment accumulation rather than the underlying melanogenic mechanisms.
The persistent and recurrent nature of dyschromia necessitates a treatment approach that targets melanogenic enzyme pathways while ensuring effective long-term management.
Luminescens®, by CMed Aesthetics S.r.L (Italy), offers a clinically robust dual-phase approach to managing hyperpigmentation by combining in-clinic Professional Serum treatment with supportive Home Cream maintenance, strategically targeting the multifaceted melanogenesis pathway.
Luminescens® offers flexibility and the ability to customise to patient- specific needs, including severity of dyschromia, skin sensitivity and therapeutic goals.
‘ITS FLEXIBILITY ALLOWS FOR CUSTOMISATION TO PATIENT- SPECIFIC NEEDS, INCLUDING SEVERITY OF DYSCHROMIA, SKIN SENSITIVITY AND THERAPEUTIC GOALS.’
Its clinical versatility extends from monotherapy to adjunctive roles, complementing common energy-based and advanced device aesthetic treatments.
Luminescens® products, according to Material Safety Data Sheets (MSDS)1 exhibit high stability, dermal compatibility and safety profiles.
Scientific basis of melanogenesis
Skin pigmentation serves as the body’s principal safeguard against UV-induced damage, driven by melanin synthesis in melanocytes via tyrosinase enzyme-mediated pathways. Excess melanin production often arises from overstimulation of melanocytes, triggered by UV radiation, inflammatory cytokines or hormonal factors such as α-MSH (α-melanocyte-stimulating hormone). The melanocortin-1 receptor (MC1R) and Microphthalmia- Associated Transcription Factor (MITF) are critical regulators within this pathway, controlling melanocyte function and melanin production2.
Luminescens® mechanism of action
Phase 1: Enzymatic inhibition of melanogenesis
Luminescens® acts at the source of pigment formation by selectively inhibiting tyrosinase, the key rate- limiting enzyme in melanin synthesis. Its advanced formula incorporates clinically established inhibitor – including tranexamic acid, ellagic acid and aminoethyl phosphinic acid – which work synergistically to reduce the enzymatic conversion of tyrosine to melanin. Additionally, ellagic acid contributes chelating properties, further disrupting melanin biosynthesis and supporting a more even, luminous complexion3.
Phase 2: Inhibition of melanin transport and melanocyte signalling
Luminescens® modulates MC1R- mediated melanocyte signalling and inhibits melanosome transfer to keratinocytes, reducing superficial pigment visibility. This interruption of melanocyte-to-keratinocyte melanin transfer disrupts visible pigment deposition at the epidermal surface.
Phase 3: Enhanced epidermal renewal and pigment removal
Keratolytic agents, notably salicylic acid, facilitate exfoliation and epidermal renewal, thus accelerating the clearance of accumulated superficial melanin and improving penetration and efficacy of active ingredients.
Phase 4: Antioxidant and barrier protection
The protocol includes antioxidants (rutin, camellia sinensis extract) and hydration agents (hyaluronic acid), to help neutralise oxidative stress involved in melanogenesis and support epidermal barrier function to reduce inflammation- driven pigmentation.
Clinical validation and outcomes
The Luminescens® protocol’s efficacy and safety were validated in the CMed Aesthetics s.r.l. Report 213E30F-1, a clinical trial conducted by Bio Basic Europe s.r.l. and the University of Pavia’s Department of Biology and Biotechnology, alongside CDC Dermo-Clinical Research Institute.
Utilising advanced Miravex Antera 3D® imaging, the trial demonstrated significant reductions in pigmentation within 30 days, further sustained and enhanced at 60 days. Patient satisfaction was high, with 95% reporting the treatment comfortable, non-invasive, and effective in improving skin uniformity and brightness4.
Luminescens® clinical protocol overview
The dual-phase protocol provides immediate clinical intervention via the Professional Serum and continuous maintenance via the Home Cream by achieving significant inhibition of tyrosinase activity, downregulation of MITF and disruption of melanosome transfer.
In-clinic Professional Serum application
Luminescens® Professional Serum incorporates active ingredients validated for melanogenesis inhibition. Administration techniques include microneedling (0.5–1.0mm depth), micro-pricking (0.3mm depth), electroporation or derma-blading, tailored to individual patient tolerance and condition severity. The standard recommended regimen involves 3 to 6 in-clinic treatments, each session typically spaced 2 to 4 weeks apart, offering precise and controlled melanogenesis suppression.
Active components of Professional Serum include: tranexamic acid (suppresses tyrosinase transcription); aminoethyl phosphinic acid (directly inhibits melanogenic enzymes); arbutin (inhibits tyrosinase activity); ellagic acid (chelates copper, essential for enzymatic melanin production); and additional antioxidants and conditioning agents1.
Home Cream maintenance regimen
The Luminescens® Home Cream enhances and maintains clinical results by providing daily melanogenesis suppression through lower-dose continuous application. Its formulation promotes sustained melanocyte inhibition, epidermal barrier support and pigment removal via gentle exfoliation. Daily use helps protect against environmental stimuli and suppress the reactivation of pigmentation. Luminescens® Home Cream may also be used independent of the Professional Serum, as part of an existing home care regime.
Home Cream key ingredients include: tranexamic acid (maintains reduced melanogenesis); phytic acid, phenylethyl resorcinol, potassium azeloyl diglycinate (complement enzymatic inhibition); retinol and citric acid (accelerate epidermal renewal and pigment clearance); glycyrrhetinic acid and sodium hyaluronate (provide anti-inflammatory and barrier reinforcement effects); and additional emollients and antioxidants1.
Luminescens®’ comprehensive approach not only offers immediate cosmetic improvement but also effectively addresses the chronic, relapsing nature of pigmentation disorders, promoting long-term uniformity of skin tone. It offers clinicians a scientifically robust, patient-friendly solution for managing complex dyschromia conditions over extended periods. AMP
Michelle Watts,
Aesthetic nurse, NEO Skin Lab, Invercargill, New Zealand
‘Both my patients and I have been extremely pleased with the experience and results of Luminescens®. The treatment itself is very comfortable for the patient and the protocol is straightforward and easy to follow for the clinician. The visible lightening of pigmentation has been genuinely impressive.
My patients are very happy with the progress so far. I’m excited to continue using Luminescens® as part of my pigmentation treatment approach; it’s a valuable addition to my treatment offerings.’
‘Luminescence® Home Cream has completely changed the texture and appearance of my skin. My main concern has been dark spots and pigmentation on my face and dark circles around my eyes. Since using this product, my dark areas are fading significantly and my skin looks and feels brighter. These are the best results I’ve had despite having used other products over the years.
I incorporated only the Home Cream into my routine – and observed a sustained significant reduction in pigmentation and increased skin clarity.’
– Patient, Fitzpatrick 4, 32 years old. 8 weeks daily use of Luminescens® Home Cream.
‘Since using the Luminescens® Home Cream, I have noticed an astonishing difference In my overall facial skin and texture. I especially notice the difference in how much this product helps my skin if I don’t use it for a day or two. I started using this cream three months ago and during this time I have seen a noticeable enhancement in my skin’s radiance. Not only is my face glowing without any makeup, but the tone has vastly improved and become even in pigmentation.
Having suffered scaring from acne and a botched microdermabrasion in my 20s, I have always suffered from rough, uneven texture on my cheeks. Luminescens® is the first product I’ve used that has noticeably diminished the scarring. Friends and acquaintences have noticed a difference in my skin, too! I have had so many compliments on the overall glow, texture and tone of my skin.’
– Patient, Fitzpatrick 2, undisclosed age. 12 weeks daily use of Luminescens® Home Cream.
Luminescens® is distributed in Australia and New Zealand by CMed Aesthetics ANZ. For more information email admin@cmedaestheticsaustralia.com or call 1300 910 101.
References:
1. CMed Aesthetics S.p.A. Material Safety Data Sheet for Luminescens Professional Serum and Home Cream, Version 03.1, April 2025.
2. Serre C, Busuttil V, Botto JM. Intrinsic and extrinsic regulation of human skin melanogenesis and pigmentation. International Journal of Cosmetic Science, 2018;40:328-347. DOI: 10.1111/ics.12466.
3. Ertam I, Mutlu B, Unal I, et al. Efficiency of ellagic acid and arbutin in melasma. Journal of Dermatological Treatment, 2008;19(4):224-229. DOI: 10.1080/09546630701839312.
4. CMed Aesthetics s.r.l. Clinical Evaluation Report 213E30F-1. Bio Basic Europe and University of Pavia, CDC Dermo-Clinical Research Institute. 2025.
